MASH

Metabolic dysfunction-associated steatohepatitis (MASH), previously known as nonalcoholic steatohepatitis (NASH).

ESMO AstraZeneca
Biotech

AstraZeneca drops MASH drug over disappointing data

AstraZeneca has ended work on one of its drugs for fatty liver disease after viewing disappointing data from a phase 2 study.
James Waldron Nov 6, 2025 5:21am
Novo Nordisk

Novo drops oncology ambitions, early-stage MASH prospects

Nov 5, 2025 7:21am
cartoon of man unplugging from outlet

Pfizer pulls the plug on 11 programs

Nov 4, 2025 2:40pm
ChatGPT said Low-poly magenta liver model centered on a pale blue background patterned with sketchy dollar signs suggestin
Favicon Fierce Pharma

Big Pharma bets big on MASH with a new combo playbook

Oct 17, 2025 9:30am
Graphic of two hands shaking under a red and purple light

Novo inks $4.7B Akero buyout to bag late-phase MASH prospect

Oct 9, 2025 8:21am
three triple doors opportunity cracked open ajar

89bio was left between a Roche and a hard place in buyout talks

Oct 2, 2025 9:55am